Reinforcing Europe as a core pillar of GenScript’s global R&D and production network
GenScript has opened its first European mRNA production site in Delft, the Netherlands, marking an expansion of the company’s global mRNA platform and strengthening Europe as a core pillar of its integrated Research and Development and production network.
The Delft facility reinforces GenScript’s transatlantic biotechnology infrastructure, allowing improved regional proximity, regulatory alignment, and supply chain resilience for European innovators developing next-generation therapies, vaccines, and advanced biologics.
Paula Río, hematopoietic innovative therapies unit, CIEMAT/CIBERER/FJD, UAM, said, “Having a local GenScript facility in the EU makes a real difference for us. The closer proximity enables more seamless collaboration, faster turnaround times, and reduced shipping delays. Working with a team that’s fully aligned with EU regulations and standards strengthens the partnership and makes day‑to‑day interactions significantly easier.”
Shawn Wu, president of GenScript EU Division, said, “Europe is not an outpost in our network; it is a core pillar of our global mRNA platform. By integrating Delft into our unified global operating system, we are delivering greater speed, regulatory alignment, and operational resilience for our partners, while maintaining one uncompromising global standard.”
The Delft site provides end-to-end mRNA workflow capabilities, including:
- Gene design and synthesis
- Vector engineering
- IVT mRNA production
- Proprietary GenCap™ mRNA capping technology
- UTR optimization and formulation support
The facility operates within GenScrip’s AI-enabled digital operating model, supporting accelerated turnaround times, process consistency, and integration with the company’s research and development and manufacturing network.
Aligning with EU regulatory standards while remaining integrated into GenScript’s global quality systems enables customers to move efficiently from research-grade mRNA to downstream development pathways across regions.
The Delft opening follows GenScript’s continued expansion of its U.S. innovation footprint, including capacity growth at its New Jersey campus, and complements its broader global operations across North America, Europe, and Asia.
Together, these investments reflect GenScript’s coordinated strategy to build resilient, high-quality growth platforms that support life science innovation from early discovery through advanced development stages.
The company’s mRNA capabilities are part of a broader integrated biotechnology ecosystem from discovery to development to manufacturing; enabling to move from idea to impact within a unified global system.
GenScript established its European Division headquarters in the Netherlands in 2021 and has steadily expanded regional operations since then. The Delft mRNA site deepens that commitment by strengthening local access to advanced mRNA technologies while maintaining global scale.
Cindy Gerhardt, managing director of Planet B.io, said, “From our first conversations, GenScript has demonstrated a strong commitment to innovation, collaboration, and scientific excellence. We’ve built a valuable partnership driven by a shared ambition to accelerate biotech research and innovation. The opening of this state-of-the-art lab strengthens the position of the Biotech Campus Delft, not only for our own community, but for the broader European biotech ecosystem.”
Sherry Shao, CEO of GenScript Biotech Corporation, said, “This expansion reflects disciplined execution of our global platform strategy. As a U.S.-founded company committed to advancing biotechnology worldwide, we continue to invest in resilient, regionally anchored infrastructure that supports innovation with speed, quality, and trust. At GenScript, ‘Scripting Possibilities’ means building the integrated global systems that allow science to move confidently from discovery to development, across regions, and at scale.”
